The current status of targeting BAFF/BLyS for autoimmune diseases
AUTOR(ES)
Ramanujam, Meera
FONTE
BioMed Central
RESUMO
It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention. The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors are expressed on most peripheral B cells. Several different BAFF antagonists are under development and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted mechanism of action in autoimmune diseases.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=546289Documentos Relacionados
- Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome
- BAFF: a local and systemic target in autoimmune diseases
- Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases
- The use of stem cells for the treatment of autoimmune diseases
- The use of stem cells for the treatment of autoimmune diseases
